Trishula Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Trishula's estimated annual revenue is currently $3.1M per year.(i)
  • Trishula's estimated revenue per employee is $155,000

Employee Data

  • Trishula has 20 Employees.(i)
  • Trishula grew their employee count by 18% last year.

Trishula's People

NameTitleEmail/Phone
1
Chief Medical OfficerReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
Executive Director Clinical OperationsReveal Email/Phone
4
Senior Director Project ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Trishula?

keywords:N/A

N/A

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Trishula News

2022-04-06 - Trishula Therapeutics Announces Promising Early Phase 1b ...

Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First...

2022-04-06 - Trishula announces results from trial of gastric cancer combo ...

Trishula Therapeutics has reported encouraging initial data from an ongoing Phase I trial of its anti-CD39 antibody TTX-030 with budigalimab...

2022-03-30 - Trishula Therapeutics Announces Oral Presentation on TTX-030 Anti-CD39 Antibody at American Association for Cancer Research (AACR) Annual Meeting

Trishula is a privately held company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody, in collaboration with AbbVie...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.8M20-77%N/A
#2
$3.4M200%N/A
#3
$4.1M2011%N/A
#4
$1.6M21-32%$178.7M
#5
$3.3M21-19%N/A